Nvidia’s Q4 revenue forecast landed slightly above estimates at $37.5 billion, but failed to satisfy high investor expectations, with shares dipping amid supply-chain constraints.
Nvidia’s Modest Forecast Raises Questions About Expectations
Even if some investors have made Nvidia the most valuable company in the world, the company still fell short of meeting their high expectations for fourth-quarter revenue, which it predicted on Wednesday, which was marginally higher than predictions.
According to Reuters, the stock of the Santa Clara, California-based firm dropped almost 2% during the course of the extended trading session. On Wednesday, they had ended the day down 0.8%.
Analysts See Mixed Signals in Nvidia’s Q4 Revenue Outlook
According to data provided by LSEG, analysts had an average estimate of $37.09 billion for the fourth quarter, while the firm predicted revenue of $37.5 billion, plus or minus 2 percent.
"The age of AI is in full steam, propelling a global shift to NVIDIA computing," stated Jensen Huang, CEO of Nvidia. "Demand for Hopper and anticipation for Blackwell - in full production - are incredible as foundation model makers scale pretraining, post-training and inference," he stated, alluding to two high-performing AI processors.
Soaring Stock Prices Reflect Investor Optimism Despite Challenges
Shares of Nvidia, which had risen by more than 20% in the preceding two months, were riding high on anticipation of the news. In the past two years, the stock has increased by more than nine times its initial value, and it has nearly quadrupled this year alone.
Nvidia has been a Wall Street darling due to its high-demand graphics processing units (GPUs), which power complex generative AI systems. However, the business has been unable to post its revenue beats due to supply-chain issues, CNA points out.
Supply Constraints Continue to Hamper Nvidia’s Performance
The company's manufacturing partner TSMC has limited capacity for innovative production procedures, which has been a bottleneck for its chip supply.
Earnings per share for the third quarter came in at 81 cents, which was lower than the 75 cents predicted by analysts.


Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 



